WO1996028468A2 - Amphiphilic peptide and analogs thereof - Google Patents

Amphiphilic peptide and analogs thereof Download PDF

Info

Publication number
WO1996028468A2
WO1996028468A2 PCT/EP1996/000844 EP9600844W WO9628468A2 WO 1996028468 A2 WO1996028468 A2 WO 1996028468A2 EP 9600844 W EP9600844 W EP 9600844W WO 9628468 A2 WO9628468 A2 WO 9628468A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
aureus
amino acid
coli
given
Prior art date
Application number
PCT/EP1996/000844
Other languages
French (fr)
Other versions
WO1996028468A3 (en
Inventor
Manmohan Bhakoo
Shail Patel
Peter Ian Stott
Original Assignee
Unilever Plc
Unilever N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Plc, Unilever N.V. filed Critical Unilever Plc
Priority to AU48316/96A priority Critical patent/AU720419B2/en
Priority to EP96904088A priority patent/EP0815128A2/en
Priority to BR9607242A priority patent/BR9607242A/en
Publication of WO1996028468A2 publication Critical patent/WO1996028468A2/en
Publication of WO1996028468A3 publication Critical patent/WO1996028468A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46N-acyl derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to amphiphilic peptides and to analogs thereof.
  • Peptides are polymers of amino acids. There are around twenty or so naturally occurring amino acids and these vary somewhat in the nature of their chemistry. By arranging specific sequences of amino acids in peptide molecules it is possible to obtain peptides which express a very broad range of chemical functionality, ranging from activity as catalysts (e.g. enzymes) to chemical messengers (e.g.
  • peptide hormones such as insulin. It is known that small changes in the sequences of peptides can have significant consequences as regards the functionality of the molecules. It is known that the synthesis of particular peptides can be directed by nucleic acid molecules of related sequences.
  • Amphiphillic peptides are characterised by an amino acid structure which provides some regions of the peptide molecule with a hydrophobic character and other regions with a hydrophillic character. It is believed that these peptides are capable of interacting with the membranes of living cells to modify the life-process of the cells. A number of amphiphillic peptides occur in nature, others have been produced by synthetic methods. WO 92/01462 discloses amphiphilic peptides for inhibiting growth of a target cell. These peptides comprise both hydrophobic and hydrophilic amino acid residues. The hydrophobic and hydrophilic balance of the amino acids can be described by reference to the hydrophobicity values quoted by Eisenberg et al. [Nature 1982 299 p371].
  • Hydrophobic residues have a value greater than zero whereas hydrophillic residues have a value of less than zero.
  • amphiphilic antimicrobial peptides can be prepared which comprise sequences selected from the group comprising:
  • the present invention extends to antimicrobial peptides having a length of 10-30 amino acid residues wherein the predicted log kill to S. aureus ATCC 6538, (L s aureus ) is greater than 5, L s aureus being given by the
  • z 1 is the molecular weight
  • z 2 is the modulus of the hydrophobicity dipole moment in
  • z 3 is the hydrophobic solvent accessible surface area
  • z 4 is the number of atoms which are greater than 8 Angstrom Units from the axis of the alpha helix
  • z 5 is the 2D radius of gyration (R xy )
  • the molecular weight is the molecular weight of the peptide in Daltons (grams per mole).
  • the hydrophobic solvent accessible surface area (in square Angstroms) is determined using the SYBYL [TM] molecular modelling package (ex. TRIPOS [TM]).
  • the hydrophilic solvent accessible surface area (in square Angstroms) is determined using the SYBYL [TM] molecular modelling package (ex. TRIPOS [TM]).
  • the X- and Y- components of the charge dipole are obtained from SYBYL after aligning the molecule such that the z-axis is along the long axis of the molecule, i.e. along the axis of the alpha-helix and the y axis is aligned with the projection into a plane orthogonal with the z-axis of the vector P wherein:
  • H i the hydrophobicity of the residue according to Eisenberg The sum of negative charge is the sum of the negative charges on the residues at pH 7.0
  • hydrophobicity dipole moment in XY-plane is the sum of vectors H + -H wherein:
  • H+ sum over hydrophobic residues of H i C i xy
  • H- sum over hydrophilic residues of H i C i xy
  • the sum of the hydrophobic and hydrophilic values is the sum of the hydrophobicity and hydrophilicity values according to Eisenberg (cit. ultra).
  • H z H z - - H z -
  • H z + is the sum of (H i * z i ) over all hydrophobic amino acids
  • H z - is the sum of (-H i * z i ) over all
  • H i is the Eisenberg (cit ultra) hydrophobicity of amino acid i
  • z. is the z coordinate of the C-alpha carbon atom of amino acid i, in units of Angstroms, using the same co-ordinate system as described above, i.e. aligning the molecule such that the Z-axis is along the long axis of the molecule
  • the number of atoms which are greater than 8 Angstrom Units from the axis of the alpha helix is obtained from SYBIL and is a simple number.
  • the closeness of fit to a square wave is s sqr , is given by the 'least squares' equation: where N is the number of amino acid residues, and H i is the hydrophobicity, i.e. s sqr is the minimum value which can be obtained by varying the offset ⁇ .
  • the radius of gyration (R zyz ) is a known measure of the sphericalness of a molecule.
  • the 2D radius of gyration (R xy ) is related to how circular the peptide appears, when looking down the alpha helix axis.
  • N is the number of atoms in the peptide. It is believed that this value is related to the ease of diffusion of the molecule through the outer membrane of the E. coli bacteria.
  • the software used was SYBYL version 6.2 (R4000 version running on a Silicon Graphics [TM] Power Challenge [TM]).
  • the peptides were built using the biopolymer module, building an individual peptide with an alpha helix
  • BIOPOLYMER ADDH Ml ( * ) ALL Charges were calculated using the Gasteiger-Huckel method. All the calculations mentioned above can be automated using computational techniques.
  • the forcefield used was the "Tripos 5.2 force field, as reported by M. Clark, R.D. Cramer III & N. van Opdenbosch; J. Comp. Chem, vol 10, p 982-1012 (1989), and amended for the SYBYL 6.0 release, as described in Appendix 2 of the "Sybyl Theory Manual.” From the above it can be seen that the parameters used in defining the peptides according to the present invention can be simply determined given the structure of the peptide and no measurement of the actual physical parameters of the peptides need be made. This process can be performed by a computer.
  • amphiphilic antimicrobial peptides are generally in the L-configuration, although it is envisaged that helices of D-amino acids would be effective.
  • the peptides according to the invention are predominantly alpha-helical and laterally amphipathic in their secondary-structure, in that they have two distinguishable faces one being predominantly hydrophilic the other being
  • the peptides are relatively short having 12-26, preferably 13-20, most preferably 15-18 amino acid residues. It is believed that these relatively short chain lengths reduce the risk of haematotoxicity.
  • the peptides are rich in basic amino acids, particularly lysine and arginine. In preferred embodiments 15-50% by number of the amino acid residues present are lysine or arginine.
  • the peptides are poor in the so-called 'beta-turn' formers, particularly lso-leucine, tyrosine and valine. In preferred embodiments of the invention less than 20% by number of the amino acid residues present are iso-leucine, tyrosine or valine.
  • the numeric ratio of the numbers of lysine or arginine residues to the numbers of iso-leucine, tyrosine or valine residues is one or more.
  • the peptides are rich in alpha-helix formers, particularly lysine, alanine and glutamine. It is preferable that at least 50% by number of the amino acid residues are lysine, alanine or glutamine.
  • the overall charge is net positive, such that the molecules are cationic at pH 7.00.
  • amino acids such as cystine, proline and histidine are not prevalent.
  • these amino acid residues are typically absent.
  • the peptides have an amphiphilicity between 0.15 and -0.34.
  • the amphiphilicity for a peptide with N residues is given as the sum from 1-N of the H n (hydrophobic face) minus the sum from 1-N of H n (hydrophilic face): where H n is the numerical hydrophobicity of the nth residue, as given by Eisenberg.
  • the peptides have a hydrophobic moment between 0.25 and 0.5.
  • the hydrophobic moment is a scalar quantity derived from the vector sum of the hydrophobic moments of the individual residues, divided by the total number of residues.
  • the hydrophobic moment for a peptide with N residues is given by:
  • N is the number of residues
  • H i is the
  • hydrophobicity of the ith residue and ⁇ i is the angle between the unit vectors of successive residues, i.e. 100 degrees of arc.
  • the peptides are have both L s >5 and L e >4, a length of 13-20 amino acids, and consist of the residues of at least three of leucine, alanine, phenylalanine, valine, isoleucine, glycine, lysine, serine, glutamine, glutamate and arginine. More preferably other amino acids than those listed above are absent.
  • the most preferable amino acids are those which show high activity against both S. aureus ( L s greater than about 5) and E coli (L e greater than about 4) these have sequences which comprise one of:
  • the peptides are not homopolymers of oligomers consisting of 3-5 amino acid residues.
  • the present invention also relates to compositions of matter comprising one or more of the peptides of the invention and the use thereof as antimicrobial (preferably antibacterial or antifungal) compositions either alone or in combination with other antimicrobial materials and treatments (including the application of heat and or pressure).
  • antimicrobial preferably antibacterial or antifungal
  • compositions find utility in disinfection, spoilage prevention, preservation and other hygiene processes. It will be apparent to the skilled worker that the peptides will find applications in many situations in which bacterial or fungal kill is required. According a further aspect of the present invention
  • the peptides can be produced by synthesis, in vivo using a nucleic acid molecule capable of directing the synthesis of the peptides. It is within the scope of the art to produce a DNA molecule which codes for the peptides disclosed herein and introduce the said DNA molecule into a cell such that the cell produces the peptides or a precursor thereof as a metabolic product. In order that the present invention may be further
  • Figure 1 Is a SAS/RGSYS (TM) vectorial analysis method (internal unfolding) on dimensions corresponding to Total charge, Hydrophile/Lipophile balance (HLB) , hydrophobic moment (as described above), and amphiphilicity (as
  • the actual bactericidal activity of these peptides was determined by a total viable counts technique using both a Gram negative bacteria (Escherichia coli ATCC 11229) and a Gram positive bacteria (Staphylococcus aureus ATCC 6538) which were cultured overnight, in nutrient broth (Oxoid (TM) Nr. 2). Cells were harvested and suspended in Ringers solution to obtain initial cell numbers of 10 6 -10 8 . Cells were incubated with the peptides aseptically in 96-well microtitre plates and relevant controls undertaken. The concentration of the peptides was 0.1-1 mg/ml. In both cases (E coli and S aureus) a log kill was determined. The measured log kill values are given in Table 2 below:
  • HLB Hydrophile/Lipophile balance
  • amphiphilicity (as described above) of the peptides. This analysis showed that these parameters could be used to predict which of a large number of peptides would be effective antibacterials. Results are presented in figure 1.
  • AMP amphiphilicity
  • EC log kill against E. coli
  • STPH log kill against S. aureus
  • HM hydrophobic moment
  • CH total positive charge
  • HLB hydrophile/ lipophile balance.
  • Table 2 shows correlations between the measured log kill (as 'act') and the predicted log kills (as 'pre') against E. coli and S. aureus for the peptides listed.
  • Predicted values were determined by means of the equation which is provided by the present invention. It can be seen that there is very good agreement between the predicted values and the observed values.
  • the peptides which show a predicted log kill of 5 or more against S . aureus or a predicted log kill 4 or more against E. coli are examples of the present invention, the other examples are comparative and show that relatively minor changes in structure can have significant consequences as regards the antimicrobial activity of the molecules.
  • the samples identified by the codes MB_nn SEQ. ID.
  • the samples coded MC_nn were peptides whose sequence showed high predicted activity.

Abstract

The invention relates to amphiphilic peptides and analogs thereof. The specification defines the molecules in three ways and discloses that antimicrobial peptides which comprise a sequence selected from the group comprising: +-++--++--+--++, +-++--++---+-+++, ++-+++-++-+++--, ++-+++-++-++++-++-, ++-+++-++--++--++-, --++--++-++--++-++, ++++-+++--+--++, ++-+++++++-++-++--, wherein + indicates a hydrophobic amino acid residue and - indicates a hydrophilic amino acid residue have improved antimicrobial properties. Specific sequences of active peptides are given. The specification also discloses two general equations which define the rule by whicc peptides falling within the scope of the invention are identified.

Description

AMPHIPHILIC PEPTIDE AND ANALOGS THEREOF
TECHNICAL FIELD
The present invention relates to amphiphilic peptides and to analogs thereof.
BACKGROUND TO THE INVENTION
Peptides are polymers of amino acids. There are around twenty or so naturally occurring amino acids and these vary somewhat in the nature of their chemistry. By arranging specific sequences of amino acids in peptide molecules it is possible to obtain peptides which express a very broad range of chemical functionality, ranging from activity as catalysts (e.g. enzymes) to chemical messengers (e.g.
peptide hormones such as insulin). It is known that small changes in the sequences of peptides can have significant consequences as regards the functionality of the molecules. It is known that the synthesis of particular peptides can be directed by nucleic acid molecules of related sequences.
Amphiphillic peptides are characterised by an amino acid structure which provides some regions of the peptide molecule with a hydrophobic character and other regions with a hydrophillic character. It is believed that these peptides are capable of interacting with the membranes of living cells to modify the life-process of the cells. A number of amphiphillic peptides occur in nature, others have been produced by synthetic methods. WO 92/01462 discloses amphiphilic peptides for inhibiting growth of a target cell. These peptides comprise both hydrophobic and hydrophilic amino acid residues. The hydrophobic and hydrophilic balance of the amino acids can be described by reference to the hydrophobicity values quoted by Eisenberg et al. [Nature 1982 299 p371].
Hydrophobic residues have a value greater than zero whereas hydrophillic residues have a value of less than zero.
For convenience some of these values are given in table 1 below, together with the codes used to represent the associated amino acid residues.
Figure imgf000004_0001
Lee at al. in Biochimica et Biophysica Acta 862 (1986) 211- 219 disclose amphiphilic antimicrobial peptides having the Structures: Ac-(LARL)1-4-NHCH3, Ac-(LLARL)2-3-NHCH3, Ac-(ARL)3- 4-NHCH3 and Ac-(LAKL)2-3-NHCH3. A general review of the field is found in Biochimica et Biophysica Acta 1197 (1994) 109-131.
Despite the sequences of several amphiphilic peptides being known it has proved difficult to identify those peptides having particularly high antimicrobial activity. While each possible peptide could, in theory, be laboriously synthesised and tested against bacteria, fungi and other microbes and it must be appreciated that given the vast number of possible amino acid sequences of an appropriate length this would take an unacceptably long time.
Accordingly, there is a need to identify and define those peptides which might be expected to be effective by a definition other than one based only on an in-vitro
functional test of a molecule which is expensive to
synthesise.
BRIEF DESCRIPTION OF THE INVENTION We have determined that improved amphiphilic antimicrobial peptides can be prepared which comprise sequences selected from the group comprising:
Figure imgf000006_0002
wherein + indicates a hydrophobic amino acid residue and - indicates a hydrophillic amino acid residue.
In particular, we have found utility in peptides having the sequences
Figure imgf000006_0001
serine, E = glutamate, Q = glutamine, T= threonine and R = arginine.
We have also determined that effective antimicrobial peptides are discriminated from ineffective peptides by a vectorial analysis on dimensions corresponding to charge, hydrophile/lipophile balance, hydrophobic moment, and amphiphilicity of the peptides whereby effective peptides fall into the region which is anti-clockwise of the amphiphilicity dimension and clockwise of the charge dimension.
We have further determined that effective peptides are discriminated from ineffective peptides by means of an equation relating certain physical properties of the peptides to their biological activity against specific microorganisms.
As discussed above, it will be appreciated that a very large number of possible peptides can be envisaged with a chain length of 10-30 amino acids. We have determined what is believed to be a general rule as regards the peptides which have effective antimicrobial properties and, as will be discussed in further detail below, have demonstrated that a strong correlation is shown between those peptides which satisfy this rule and those which have effective antimicrobial properties. Conversely, it appears that the majority of the peptides which exhibit properties outside of the scope of the rule do not show effective
antimicrobial properties.
Accordingly, the present invention extends to antimicrobial peptides having a length of 10-30 amino acid residues wherein the predicted log kill to S. aureus ATCC 6538, (Ls aureus) is greater than 5, Ls aureus being given by the
Figure imgf000008_0002
wherein : z1= sum of the hydrophobic and hydrophilic values z2= Y component of charge dipole
z3= sum of negative charge
z4= closeness of fit to sine wave
z5= X component of charge dipole
z= closeness of fit to square wave
Figure imgf000008_0001
Figure imgf000009_0001
Figure imgf000010_0001
The present invention also extends to antimicrobial peptides having a length of 10-30 amino acid residues wherein the predicted log kill to E. coli ATCC 11229, (LE coli) is greater than 4, LE coli being given by the equation LE coli = y[27] * (4.41875) + (3.615)
Figure imgf000011_0002
z0 is the LS aureus,
z1 is the molecular weight,
z2 is the modulus of the hydrophobicity dipole moment in
Z-plane,
z3 is the hydrophobic solvent accessible surface area, z4 is the number of atoms which are greater than 8 Angstrom Units from the axis of the alpha helix,
z5 is the 2D radius of gyration (Rxy)
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
While the above-mentioned equations seem complex it is a simple computational task to determine whether any
particular peptide falls within the scope of the rule or not. The equation is that of a so-called neural net and the general type is familiar to those engaged in this art.
As will be discussed in further detail and demonstrated by way of example below, it is possible, given the rule, to search for sequences which obey this rule and consequently would be expected to exhibit significant antimicrobial properties. The synthesis of the peptides which have been thus identified as potentially antimicrobial is therefore a significantly simpler task than the synthesis of peptides and the selection of desirable molecules on the basis of their measured antimicrobial properties.
DETAILED DESCRIPTION OF THE INVENTION: In the current specification, the following terms are used:
The molecular weight, is the molecular weight of the peptide in Daltons (grams per mole). The hydrophobic solvent accessible surface area (in square Angstroms) is determined using the SYBYL [TM] molecular modelling package (ex. TRIPOS [TM]). The hydrophilic solvent accessible surface area (in square Angstroms) is determined using the SYBYL [TM] molecular modelling package (ex. TRIPOS [TM]).
The X- and Y- components of the charge dipole are obtained from SYBYL after aligning the molecule such that the z-axis is along the long axis of the molecule, i.e. along the axis of the alpha-helix and the y axis is aligned with the projection into a plane orthogonal with the z-axis of the vector P wherein:
P = sum over hydrophobic residues of HiCi, wherein, Ci= centre of mass of the alpha-carbon of each
residue, and,
Hi= the hydrophobicity of the residue according to Eisenberg The sum of negative charge is the sum of the negative charges on the residues at pH 7.0
The hydrophobicity dipole moment in XY-plane is the sum of vectors H+-H wherein:
H+ = sum over hydrophobic residues of HiCi xy, and, H- = sum over hydrophilic residues of HiCi xy
The sum of the hydrophobic and hydrophilic values is the sum of the hydrophobicity and hydrophilicity values according to Eisenberg (cit. ultra).
The modulus of the hydrophobicity dipole moment in the Z-plane. This hydrophobicity dipole moment Hz is given by:
Hz = Hz- - Hz- where Hz + is the sum of (Hi * zi) over all hydrophobic amino acids, and, Hz- is the sum of (-Hi * zi) over all
hydrophilic amino acids, Hi is the Eisenberg (cit ultra) hydrophobicity of amino acid i, and z. is the z coordinate of the C-alpha carbon atom of amino acid i, in units of Angstroms, using the same co-ordinate system as described above, i.e. aligning the molecule such that the Z-axis is along the long axis of the molecule The number of atoms which are greater than 8 Angstrom Units from the axis of the alpha helix is obtained from SYBIL and is a simple number. The closeness of fit to a sine wave, ssin, is given by the 'least squares' equation:
Figure imgf000016_0001
where N is the number of peptides, ssin is the minimum value which can be obtained by varying the offset θ, and where Hi is in this instance normalised such that the largest positive and largest negative value of hydrophobicity for the residues are set at 1 and -1 respectively.
The closeness of fit to a square wave is ssqr, is given by the 'least squares' equation:
Figure imgf000016_0002
where N is the number of amino acid residues, and Hi is the hydrophobicity, i.e. ssqr is the minimum value which can be obtained by varying the offset θ. The radius of gyration (Rzyz) is a known measure of the sphericalness of a molecule. The 2D radius of gyration (Rxy) is related to how circular the peptide appears, when looking down the alpha helix axis.
Figure imgf000016_0003
Where xi and yi are the coordinates of atom i. N is the number of atoms in the peptide. It is believed that this value is related to the ease of diffusion of the molecule through the outer membrane of the E. coli bacteria. The software used was SYBYL version 6.2 (R4000 version running on a Silicon Graphics [TM] Power Challenge [TM]). The peptides were built using the biopolymer module, building an individual peptide with an alpha helix
conformation using the command BIOPOLYMER BUILD M1
<SEQUENCE> ALPHA_HELIX. Hydrogen atoms were then added using the command BIOPOLYMER ADDH M1 ( * ) ESSENTIAL_ONLY. The peptide was then orientated as specified earlier, then the protein structure was refined using the following commands:
BIOPOLYMER ADD_SIDECHAINS Ml ( * )
BIOPOLYMER FIX_END_GROUPS Ml NEUTRAL
BIOPOLYMER ADDH Ml ( * ) ALL Charges were calculated using the Gasteiger-Huckel method. All the calculations mentioned above can be automated using computational techniques.
The forcefield used was the "Tripos 5.2 force field, as reported by M. Clark, R.D. Cramer III & N. van Opdenbosch; J. Comp. Chem, vol 10, p 982-1012 (1989), and amended for the SYBYL 6.0 release, as described in Appendix 2 of the "Sybyl Theory Manual." From the above it can be seen that the parameters used in defining the peptides according to the present invention can be simply determined given the structure of the peptide and no measurement of the actual physical parameters of the peptides need be made. This process can be performed by a computer. Given that there are a finite number of peptide molecules having 10-30 amino acids it is a computationally simple task to determine the sequences and parameters of each of these peptides and then determine whether the peptide has a predicted log kill against E . coli or S .
aureus above the required value. The peptides mentioned above have several additional features which make them particularly suitable as
amphiphilic antimicrobial peptides. The peptides are generally in the L-configuration, although it is envisaged that helices of D-amino acids would be effective.
The peptides according to the invention are predominantly alpha-helical and laterally amphipathic in their secondary-structure, in that they have two distinguishable faces one being predominantly hydrophilic the other being
predominantly hydrophobic. The peptides are relatively short having 12-26, preferably 13-20, most preferably 15-18 amino acid residues. It is believed that these relatively short chain lengths reduce the risk of haematotoxicity. Preferably, the peptides are rich in basic amino acids, particularly lysine and arginine. In preferred embodiments 15-50% by number of the amino acid residues present are lysine or arginine. Preferably, the peptides are poor in the so-called 'beta-turn' formers, particularly lso-leucine, tyrosine and valine. In preferred embodiments of the invention less than 20% by number of the amino acid residues present are iso-leucine, tyrosine or valine.
It is preferable that the numeric ratio of the numbers of lysine or arginine residues to the numbers of iso-leucine, tyrosine or valine residues is one or more. Preferably, the peptides are rich in alpha-helix formers, particularly lysine, alanine and glutamine. It is preferable that at least 50% by number of the amino acid residues are lysine, alanine or glutamine.
Preferably, the overall charge is net positive, such that the molecules are cationic at pH 7.00.
Preferably, specific amino acids, such as cystine, proline and histidine are not prevalent. In embodiments of the invention these amino acid residues are typically absent.
Preferably, the peptides have an amphiphilicity between 0.15 and -0.34. The amphiphilicity for a peptide with N residues is given as the sum from 1-N of the Hn (hydrophobic face) minus the sum from 1-N of Hn(hydrophilic face): where Hn is the numerical hydrophobicity of the nth residue, as given by Eisenberg.
Preferably, the peptides have a hydrophobic moment between 0.25 and 0.5. The hydrophobic moment is a scalar quantity derived from the vector sum of the hydrophobic moments of the individual residues, divided by the total number of residues. The hydrophobic moment for a peptide with N residues is given by:
Figure imgf000019_0001
wherein N is the number of residues, Hi is the
hydrophobicity of the ith residue and δi is the angle between the unit vectors of successive residues, i.e. 100 degrees of arc.
Preferably, the peptides are have both Ls>5 and Le>4, a length of 13-20 amino acids, and consist of the residues of at least three of leucine, alanine, phenylalanine, valine, isoleucine, glycine, lysine, serine, glutamine, glutamate and arginine. More preferably other amino acids than those listed above are absent. The most preferable amino acids are those which show high activity against both S. aureus ( Ls greater than about 5) and E coli (Le greater than about 4) these have sequences which comprise one of:
Figure imgf000020_0001
Preferably the peptides are not homopolymers of oligomers consisting of 3-5 amino acid residues.
The present invention also relates to compositions of matter comprising one or more of the peptides of the invention and the use thereof as antimicrobial (preferably antibacterial or antifungal) compositions either alone or in combination with other antimicrobial materials and treatments (including the application of heat and or pressure). The afore-mentioned compositions find utility in disinfection, spoilage prevention, preservation and other hygiene processes. It will be apparent to the skilled worker that the peptides will find applications in many situations in which bacterial or fungal kill is required. According a further aspect of the present invention
subsists in a method for the disinfection of surfaces which comprises the step of treating a surface with a composition comprising a peptide according to any one of claims 1-4 as appended hereto. While the peptides disclosed herein have been synthesised in vitro by the stepwise method of Merifield, it is
envisaged that the peptides can be produced by synthesis, in vivo using a nucleic acid molecule capable of directing the synthesis of the peptides. It is within the scope of the art to produce a DNA molecule which codes for the peptides disclosed herein and introduce the said DNA molecule into a cell such that the cell produces the peptides or a precursor thereof as a metabolic product. In order that the present invention may be further
understood it will be described hereinafter with reference to the accompanying figure wherein:
Figure 1: Is a SAS/RGSYS (TM) vectorial analysis method (internal unfolding) on dimensions corresponding to Total charge, Hydrophile/Lipophile balance (HLB) , hydrophobic moment (as described above), and amphiphilicity (as
described above) of the peptides.
EXAMPLES
The peptides listed in Table 2 below were prepared by
Merifield Solid Phase Synthesis (R. B. Merrifield J.Am.
Chem. Soc. [1963] volume 85 page 2149) .
The actual bactericidal activity of these peptides was determined by a total viable counts technique using both a Gram negative bacteria (Escherichia coli ATCC 11229) and a Gram positive bacteria (Staphylococcus aureus ATCC 6538) which were cultured overnight, in nutrient broth (Oxoid (TM) Nr. 2). Cells were harvested and suspended in Ringers solution to obtain initial cell numbers of 106-108. Cells were incubated with the peptides aseptically in 96-well microtitre plates and relevant controls undertaken. The concentration of the peptides was 0.1-1 mg/ml. In both cases (E coli and S aureus) a log kill was determined. The measured log kill values are given in Table 2 below:
The results were analysed by a SAS/RGSYS (TM) vectorial analysis method (internal unfolding) on dimensions
corresponding to Total charge, Hydrophile/Lipophile balance (HLB), hydrophobic moment (as described above), and
amphiphilicity (as described above) of the peptides. This analysis showed that these parameters could be used to predict which of a large number of peptides would be effective antibacterials. Results are presented in figure 1. In figure 1, AMP is amphiphilicity, EC is log kill against E. coli, STPH is log kill against S. aureus, HM is hydrophobic moment, CH is total positive charge and HLB is hydrophile/ lipophile balance.
Table 2 below shows correlations between the measured log kill (as 'act') and the predicted log kills (as 'pre') against E. coli and S. aureus for the peptides listed.
Predicted values were determined by means of the equation which is provided by the present invention. It can be seen that there is very good agreement between the predicted values and the observed values. The peptides which show a predicted log kill of 5 or more against S . aureus or a predicted log kill 4 or more against E. coli are examples of the present invention, the other examples are comparative and show that relatively minor changes in structure can have significant consequences as regards the antimicrobial activity of the molecules. The samples identified by the codes MB_nn (SEQ. ID. ) were of peptides which were identified as possibly antimicrobial without reference to the predictive equation provided by the present invention. The samples coded MC_nn (SEQ. ID. ) were peptides whose sequence showed high predicted activity. These molecules were synthesised using the
Merifield Solid Phase Synthesis method and the actual activity of the molecules against S . aureus was determined. It can be seen that there is a good correlation between the predicted activity and the observed activity of these molecules. A computer-assisted method was used to arrive at the sequences of the CM-n (SEQ. ID. ) series of
examples. Of these it can be seen that there is again a high correlation between the predicted and expected
antimicrobial activity.
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001

Claims

1. Amphiphilic antimicrobial peptides which comprise a sequence selected from the group comprising:
Figure imgf000032_0001
2. Peptides according to claim 1 having a sequence
selected from the group comprising
Figure imgf000032_0002
Figure imgf000033_0001
3. Antimicrobial peptides having a length of 10-30 amino acid residues wherein the predicted log kill to S. aureus ATCC 6538, (LS aureus) is greater than 5, LS aureus being given by the equation LS aureus = y[25] *
(4.8362068) + (3.5316215) wherein:
Figure imgf000033_0002
Figure imgf000034_0001
Figure imgf000035_0001
4. Antimicrobial peptides having a length of 10-30 amino acid residues wherein the predicted log kill to E. coli ATCC 11229, (LE coli) is greater than 4, LE coli being given by the equation LE coli = y[27] * (4.41875) + (3.615); wherein,
Figure imgf000036_0002
z0 is the LS aureus,
z1 is the molecular weight,
z2 is the modulus of the hydrophobicity dipole moment in Z-plane,
z3 is the hydrophobic solvent accessible surface area, z4 is the number of atoms which are' greater than 8 Angstrom Units from the axis of the alpha helix,
z5 is the 2D radius of gyration (Rxy)
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
5. A method for the disinfection of surfaces which comprises the step of treating a surface with a composition comprising a peptide according to any one of claims 1-4.
PCT/EP1996/000844 1995-03-09 1996-02-27 Amphiphilic peptide and analogs thereof WO1996028468A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU48316/96A AU720419B2 (en) 1995-03-09 1996-02-27 Amphiphilic peptide and analogs thereof
EP96904088A EP0815128A2 (en) 1995-03-09 1996-02-27 Amphiphilic peptide and analogs thereof
BR9607242A BR9607242A (en) 1995-03-09 1996-02-27 Amphiphilic antimicrobial peptides and process for disinfecting surfaces

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9504761.9A GB9504761D0 (en) 1995-03-09 1995-03-09 Amphiphilic peptide and analogs thereof
GB9504761.9 1995-03-09

Publications (2)

Publication Number Publication Date
WO1996028468A2 true WO1996028468A2 (en) 1996-09-19
WO1996028468A3 WO1996028468A3 (en) 1997-04-17

Family

ID=10770918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/000844 WO1996028468A2 (en) 1995-03-09 1996-02-27 Amphiphilic peptide and analogs thereof

Country Status (6)

Country Link
EP (1) EP0815128A2 (en)
KR (1) KR19980702853A (en)
AU (1) AU720419B2 (en)
BR (1) BR9607242A (en)
GB (1) GB9504761D0 (en)
WO (1) WO1996028468A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1023836A1 (en) * 1999-01-26 2000-08-02 Unilever N.V. Compositions and methods for inhibiting the growth of fungi
WO2001010887A2 (en) * 1999-08-10 2001-02-15 Biomedicom Creative Biomedical Computing Ltd. Multi-functional antimicrobial peptides
US6280725B1 (en) 2000-01-18 2001-08-28 Lipton, Division Of Conopco, Inc. Compositions and methods for inhibiting the growth of fungi
EP1049709B1 (en) * 1998-01-22 2003-09-24 Samyang Genex Co., Ltd. Antimicrobial peptides
EP1541584A1 (en) * 2002-09-02 2005-06-15 Shanghai Hi-Tech United Bio-Technological Research &amp; Development Co., Ltd. A group of novel synthetic antibiotic peptides
WO2006020121A1 (en) * 2004-07-14 2006-02-23 Gene Tools, Llc Peptide composition and method for delivering substances into the cytosol of cells
EP2021364A1 (en) * 2006-05-16 2009-02-11 Dermagen AB Improved antimicrobial peptides
WO2010091651A3 (en) * 2009-02-12 2010-11-11 Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. Novel antimicrobial peptides
WO2013124436A1 (en) * 2012-02-23 2013-08-29 University Of East London Synthetic anti-microbial peptides with a minority of cationic and a majority hydrophobic side chains
US9259483B2 (en) 2011-11-24 2016-02-16 Positec Power Tools (Suzhou) Co Ltd Peptide sequence design and use thereof for peptide-mediated siRNA delivery
US9481719B2 (en) 2009-06-03 2016-11-01 Basf Se Recombinant production of peptides
US9745348B2 (en) 2011-09-14 2017-08-29 The University Of Manchester Short designed peptides possessing selective actions against bacteria and cancer cells

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012015A1 (en) * 1990-02-08 1991-08-22 Magainin Sciences Inc. Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell
WO1992001462A1 (en) * 1990-07-19 1992-02-06 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5221732A (en) * 1988-12-06 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial magainin modified peptides
US5225399A (en) * 1991-04-15 1993-07-06 The Children's Hospital Of Philadelphia Antimicrobial amphiphilic peptides
US5239059A (en) * 1991-05-10 1993-08-24 The Children's Hospital Of Philadelphia Ion-channel forming peptides
WO1994012206A1 (en) * 1992-12-03 1994-06-09 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
WO1994013697A1 (en) * 1992-12-07 1994-06-23 Magainin Pharmaceuticals, Inc. Treatment of septic shock with conjugated biologically active peptides
WO1994019369A1 (en) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504260A (en) * 1990-07-19 1994-05-19 ザ スクリップス リサーチ インスティテュート Amphipathic peptide compositions and analogs thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221732A (en) * 1988-12-06 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial magainin modified peptides
WO1991012015A1 (en) * 1990-02-08 1991-08-22 Magainin Sciences Inc. Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell
WO1992001462A1 (en) * 1990-07-19 1992-02-06 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5294605A (en) * 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5225399A (en) * 1991-04-15 1993-07-06 The Children's Hospital Of Philadelphia Antimicrobial amphiphilic peptides
US5239059A (en) * 1991-05-10 1993-08-24 The Children's Hospital Of Philadelphia Ion-channel forming peptides
WO1994012206A1 (en) * 1992-12-03 1994-06-09 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
WO1994013697A1 (en) * 1992-12-07 1994-06-23 Magainin Pharmaceuticals, Inc. Treatment of septic shock with conjugated biologically active peptides
WO1994019369A1 (en) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL CYBERNETICS, vol. 73, no. 3, August 1995, HEIDELBERG DE, pages 245-254, XP000525997 SCHNEIDER G. ET AL.: "Development of simple fitness landscapes for peptides by artificial neural filter systems" *
CABIOS COMPUTER APPLICATIONS IN THE BIOSCIENCES, vol. 10, no. 6, December 1994, OXFORD GB, pages 635-645, XP000608600 SCHNEIDER G. ET AL.: "Artificial neural networks and simulated molecular evolution are potential tools for sequence-oriented protein design" *
JOURNAL OF CHROMATOGRAPHY, vol. 625, 20 November 1992, AMSTERDAM NL, pages 199-206, XP000573322 BLONDELLE S.E. ET AL.: "Evaluation of peptide-peptide interactions using reversed phase high-performance liquid chromatographgy" *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1049709B1 (en) * 1998-01-22 2003-09-24 Samyang Genex Co., Ltd. Antimicrobial peptides
EP1023836A1 (en) * 1999-01-26 2000-08-02 Unilever N.V. Compositions and methods for inhibiting the growth of fungi
WO2001010887A2 (en) * 1999-08-10 2001-02-15 Biomedicom Creative Biomedical Computing Ltd. Multi-functional antimicrobial peptides
WO2001010887A3 (en) * 1999-08-10 2001-07-05 Biomedicom Creative Biomedical Multi-functional antimicrobial peptides
US6280725B1 (en) 2000-01-18 2001-08-28 Lipton, Division Of Conopco, Inc. Compositions and methods for inhibiting the growth of fungi
EP1541584A1 (en) * 2002-09-02 2005-06-15 Shanghai Hi-Tech United Bio-Technological Research &amp; Development Co., Ltd. A group of novel synthetic antibiotic peptides
EP1541584A4 (en) * 2002-09-02 2007-12-05 Shanghai Hi Tech United Bio Te A group of novel synthetic antibiotic peptides
WO2006020121A1 (en) * 2004-07-14 2006-02-23 Gene Tools, Llc Peptide composition and method for delivering substances into the cytosol of cells
US7084248B2 (en) * 2004-07-14 2006-08-01 Gene Tools, Llc Peptide composition and method for delivering substances into the cytosol of cells
EP2021364A4 (en) * 2006-05-16 2009-11-25 Dermagen Ab Improved antimicrobial peptides
EP2021364A1 (en) * 2006-05-16 2009-02-11 Dermagen AB Improved antimicrobial peptides
US8227406B2 (en) 2006-05-16 2012-07-24 Dermagen Ab Antimicrobial peptides
AU2007250558B2 (en) * 2006-05-16 2012-10-25 Pergamum Ab Improved antimicrobial peptides
WO2010091651A3 (en) * 2009-02-12 2010-11-11 Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. Novel antimicrobial peptides
US9481719B2 (en) 2009-06-03 2016-11-01 Basf Se Recombinant production of peptides
US9745348B2 (en) 2011-09-14 2017-08-29 The University Of Manchester Short designed peptides possessing selective actions against bacteria and cancer cells
US9259483B2 (en) 2011-11-24 2016-02-16 Positec Power Tools (Suzhou) Co Ltd Peptide sequence design and use thereof for peptide-mediated siRNA delivery
US9603946B2 (en) 2011-11-24 2017-03-28 Positec Power Tools (Suzhou) Co Ltd Peptide sequence design and use thereof for peptide-mediated siRNA delivery
US9950073B2 (en) 2011-11-24 2018-04-24 Positec Power Tools (Suzhou) Co. Ltd. Peptide sequence design and use thereof for peptide-mediated siRNA delivery
WO2013124436A1 (en) * 2012-02-23 2013-08-29 University Of East London Synthetic anti-microbial peptides with a minority of cationic and a majority hydrophobic side chains

Also Published As

Publication number Publication date
AU720419B2 (en) 2000-06-01
KR19980702853A (en) 1998-08-05
GB9504761D0 (en) 1995-04-26
WO1996028468A3 (en) 1997-04-17
EP0815128A2 (en) 1998-01-07
BR9607242A (en) 1997-11-11
AU4831696A (en) 1996-10-02

Similar Documents

Publication Publication Date Title
Yoshida et al. Using evolutionary algorithms and machine learning to explore sequence space for the discovery of antimicrobial peptides
WO1996028468A2 (en) Amphiphilic peptide and analogs thereof
Hagler et al. Computer simulation of the conformational properties of oligopeptides. Comparison of theoretical methods and analysis of experimental results
Chou et al. Energetics of interactions of regular structural elements in proteins
Lee et al. Structure–activity relationships of de novo designed cyclic antimicrobial peptides based on gramicidin S
Elrod-Erickson et al. High-resolution structures of variant Zif268–DNA complexes: implications for understanding zinc finger–DNA recognition
CN101395173B (en) Template-fixed peptidomimetics with antimicrobial activity
Sarai et al. Origin of DNA helical structure and its sequence dependence
Arkin et al. Structural perspectives of phospholamban, a helical transmembrane pentamer
Freund et al. The solution structure of the lantibiotic gallidermin
Phoenix et al. The hydrophobic moment and its use in the classification of amphiphilic structures
de Souza et al. Investigating the effect of different positioning of lysine residues along the peptide chain of mastoparans for their secondary structures and biological activities
Mer et al. Solution structure of PMP-D2, a 35-residue peptide isolated from the insect Locusta migratoria
Langham et al. Correlation between simulated physicochemical properties and hemolycity of protegrin-like antimicrobial peptides: predicting experimental toxicity
Hazam et al. Topological effects on the designability and bactericidal potency of antimicrobial peptides
Martino et al. On the occurrence of polyproline II structure in elastin
Lauble et al. Three-dimensional structure of d (GGGATCCC) in the crystalline state
Ghosh et al. Two dimensional materials are non-nanotoxic and biocompatible towards cyclotides: evidence from classical molecular dynamics simulations
Lai et al. Roles of salt and conformation in the biological and physicochemical behavior of protegrin-1 and designed analogues: correlation of antimicrobial, hemolytic, and lipid bilayer-perturbing activities
CN113185576B (en) Beta-hairpin type low-toxicity broad-spectrum antibacterial peptide with RRRF corner and application thereof
EP2120983A2 (en) Novel anti-microbial peptidomimetic compounds and methods to calculate anti-microbial activity
Shishkov et al. Tritium planigraphy of biological systems
Möhle et al. Peptides and peptoids-a systematic structure comparison
Oie et al. Ab initio study of catalyzed and uncatalyzed amide bond formation as a model for peptide bond formation: Ammonia‐formic acid and ammonia‐glycine reactions
Castro et al. Conformational and thermodynamic properties of non-canonical α, α-dialkyl glycines in the peptaibol alamethicin: Molecular dynamics studies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996904088

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019970706260

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996904088

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970706260

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019970706260

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996904088

Country of ref document: EP